Pharmaceuticals News and Research

RSS

Myelin Repair Foundation enters into agreement with NIH to assess MRF-008 for multiple sclerosis

The Myelin Repair Foundation today announced it has entered a Cooperative Research and Development Agreement with the National Institutes of Health to assess MRF-008, as a potential therapeutic for multiple sclerosis. This CRADA will facilitate collaboration between the MRF and National Institute of Neurological Disorders and Stroke at the NIH Clinical Center to study MRF-008, a drug identified by the MRF as a potential neuroprotective therapeutic to enhance repair in multiple sclerosis patients.

27 Jan 2014

DKFZ, AstraZeneca EORTC join Worldwide Innovative Network Consortium

The Worldwide Innovative Network (WIN) Consortium in personalized cancer medicine is proud to announce that AstraZeneca, DKFZ and EORTC have joined the Consortium.

27 Jan 2014

New innovations in booming 3D printing industry

As global demand for new innovations in the booming 3D printing industry grows exponentially by the day, Rainbow Coral Corp. (OTCBB: RBCC) is preparing to capitalize with groundbreaking new products for the 3D marketplace.

27 Jan 2014

New method allows for large-scale generation of human embryonic stem cells

A new method allows for large-scale generation of human embryonic stem cells of high clinical quality. It also allows for production of such cells without destroying any human embryos.

27 Jan 2014

Dyzle, KPN offer integrated platform for monitoring real-time data analytics in food and pharmaceutical industries

KPN, the leading telecommunications and ICT service provider in the Netherlands, and Dyzle BV, the global leader in measuring and analyzing business process data for the cold chain in real-time, have announced a collaboration to offer an integrated platform for monitoring, tracking, and providing real-time data analytics and visualization for the food and pharmaceutical industries.

27 Jan 2014

FDA meeting streamlines pathway to initial U.S. approval of Provectus's PV-10 oncology drug

Provectus Biopharmaceuticals, Inc. (PVCT), a development-stage oncology and dermatology biopharmaceutical company, today announced that it has received the official minutes from the Type C meeting held with the FDA's Division of Oncology Products 2 on December 16, 2013.

27 Jan 2014

NextSource BioTechnology announces product re-launch, market availability of Lomustine in U.S.

NextSource BioTechnology, LLC, (NSB), an emerging Specialty Pharmaceutical Manufacturing and Marketing Company focused on Consolidating, Re-Branding and Launching "Matured & Orphan Drugs," has announced its most recent product Lomustine (CCNU), formerly known as CeeNu® by Bristol-Myers Squibb (BMS), which has officially been removed from the U.S. Food & Drug Administration (FDA) Drug Shortage List.

27 Jan 2014

ResearchDx expands operations to focus on Middle East clinical laboratory and diagnostics markets

ResearchDx, LLC of Irvine, California, USA today announced an expansion of its operations to focus on the important Middle East clinical laboratory and diagnostics markets.

27 Jan 2014

Active Biotech, Teva remain committed to NERVENTRA clinical development program for multiple sclerosis

Teva Pharmaceutical Industries Ltd. and Active Biotech (NASDAQ OMX NORDIC: ACTI) announced today that both companies remain committed to the NERVENTRA® (laquinimod) clinical development program for multiple sclerosis (MS) following the announcement of a negative opinion for the treatment of relapsing-remitting multiple sclerosis (RRMS) by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA).

27 Jan 2014

Hols conveys product’s safety and cost effectiveness to managed care groups

Health Outcomes Liaisons (HOLs) play a critical role in conveying a therapy's safety and cost effectiveness to managed care groups. With billions in sales riding on effectively communicating with these organizations regarding products' cost effectiveness and safety, the biopharmaceutical industry has turned to HOLs to fill this critical communication role.

27 Jan 2014

Researchers develop novel compound known to reverse spread of malignant breast cancer cells

Researchers at Cardiff University are developing a novel compound known to reverse the spread of malignant breast cancer cells.

26 Jan 2014

Cleveland Clinic: Process that turns HDL cholesterol bad discovered

Cleveland Clinic researchers have discovered the process by which high-density lipoprotein (HDL) - the so-called "good cholesterol" - becomes dysfunctional, loses its cardio-protective properties, and instead promotes inflammation and atherosclerosis, or the clogging and hardening of the arteries.

26 Jan 2014

Cantrell Drug Company amends FDA registration to include 503B compounding outsourcing facility

Cantrell Drug Company today announced amendment of its U.S. Food and Drug Administration (FDA) registration to include the new 503B "compounding outsourcing facility" designation established under the recently passed Drug Quality and Security Act so that it can continue to serve patients nationwide with sterile medications that meet the most exacting quality standards.

25 Jan 2014

Actavis signs agreement with Zhejiang Chiral to acquire Actavis Foshan, China

Actavis plc today announced that it has signed and completed an agreement for Zhejiang Chiral Medicine Chemicals Co., Ltd to acquire Actavis' interest in Actavis (Foshan) Pharmaceuticals Co., Ltd., an Actavis subsidiary based in Foshan, China.

25 Jan 2014

UM professors receive grant to help athletes, military members suffering from traumatic brain injury

Athletes, members of the military and others suffering from traumatic brain injury may benefit from research conducted by two University of Montana faculty members through a new $300,000 grant awarded by General Electric Co. and the National Football League.

25 Jan 2014

Bristol-Myers Squibb fourth quarter 2013 revenues increase 6% to $4.4 billion

Bristol-Myers Squibb Company today reported results for the fourth quarter and full year of 2013. The fourth quarter was highlighted by the company's announcement to sell its diabetes business as part of the continued evolution of its successful BioPharma strategy to a specialty care model. The company achieved important regulatory milestones in the quarter for Eliquis in the U.S., daclatasvir/asunaprevir in Japan, daclatasvir in Europe and Farxiga in the U.S. In addition, the company provided financial guidance for 2014.

24 Jan 2014

Extracts from birch tree helps damaged skin around wounds to regenerate more quickly

Extracts from the birch tree have served for centuries as a traditional means of helping the damaged skin around wounds to regenerate more quickly. Prof. Dr. Irmgard Merfort from the Institute of Pharmaceutical Sciences of the University of Freiburg and her team have now explained the molecular mechanism behind the wound-healing effect of an extract from the outer white layer of the tree's bark.

24 Jan 2014

Mylan Pharmaceuticals launches Repaglinide Tablets, 0.5 mg, 1 mg and 2 mg

Mylan Inc. today announced that its U.S.-based subsidiary Mylan Pharmaceuticals Inc. has launched Repaglinide Tablets, 0.5 mg, 1 mg and 2 mg. This product is the generic version of Novo Nordisk's Prandin, which is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

24 Jan 2014

BRI receives grant to lead ITN for evaluating novel therapies for transplantation, allergy and autoimmune diseases

The National Institutes of Health has awarded Benaroya Research Institute at Virginia Mason a 7-year grant to lead the Immune Tolerance Network.

24 Jan 2014

Prosonix announces positive top-line results from PSX1002 Phase 2 study for COPD treatment

Prosonix, an innovative speciality pharmaceutical company developing a portfolio of inhaled Respiratory Medicines by Design, announces positive top-line results from its Phase 2 clinical study with PSX1002 in patients with moderate to severe chronic obstructive pulmonary disease.

23 Jan 2014

Pharmaceuticals News and Research

Myelin Repair Foundation enters into agreement with NIH to assess MRF-008 for multiple sclerosis

DKFZ, AstraZeneca EORTC join Worldwide Innovative Network Consortium

New innovations in booming 3D printing industry

New method allows for large-scale generation of human embryonic stem cells

Dyzle, KPN offer integrated platform for monitoring real-time data analytics in food and pharmaceutical industries

FDA meeting streamlines pathway to initial U.S. approval of Provectus's PV-10 oncology drug

NextSource BioTechnology announces product re-launch, market availability of Lomustine in U.S.

ResearchDx expands operations to focus on Middle East clinical laboratory and diagnostics markets

Active Biotech, Teva remain committed to NERVENTRA clinical development program for multiple sclerosis

Hols conveys product’s safety and cost effectiveness to managed care groups

Researchers develop novel compound known to reverse spread of malignant breast cancer cells

Cleveland Clinic: Process that turns HDL cholesterol bad discovered

Cantrell Drug Company amends FDA registration to include 503B compounding outsourcing facility

Actavis signs agreement with Zhejiang Chiral to acquire Actavis Foshan, China

UM professors receive grant to help athletes, military members suffering from traumatic brain injury

Bristol-Myers Squibb fourth quarter 2013 revenues increase 6% to $4.4 billion

Extracts from birch tree helps damaged skin around wounds to regenerate more quickly

Mylan Pharmaceuticals launches Repaglinide Tablets, 0.5 mg, 1 mg and 2 mg

BRI receives grant to lead ITN for evaluating novel therapies for transplantation, allergy and autoimmune diseases

Prosonix announces positive top-line results from PSX1002 Phase 2 study for COPD treatment

Event guide: World ADC San Diego eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence